Human medicinal products
International Regulatory Affairs
As you take your products to international markets, we support you in dossier preparation, submission and follow-up in line with the legislation of the target country.
Scope of service
Our scope of services
- Support and guidance in preparing marketing authorisation dossiers in line with target-country legislation
- Coordination with distributors; follow-up and reporting of authorisation procedures in each country
- Meetings with local representatives and authorities in the EU, the CIS and Eurasian Economic Union, the Gulf, MENA and ASEAN regions
- Preparation of variation applications abroad
- Preparation of application dossiers for GMP inspections abroad
- Dossier format conversions: CTD, eCTD, ACTD, NeeS and EAEU format
- CPP and free sale certificate applications
Frequently asked questions
Common questions
Answers are based on ICH M4 (CTD) and the eCTD specifications, the ASEAN ACTD/ACTR, Decision No. 78 of the Council of the Eurasian Economic Commission (as amended) and the Gulf centralised registration rules, and are for general information only. As country requirements change, the target authority’s current guidance prevails for every application.
In which regions do you provide registration support?
We support the preparation, submission and follow-up of marketing authorisation dossiers in the European Union (EU), the Middle East and North Africa (MENA) and the Gulf states, the Association of Southeast Asian Nations (ASEAN), and the Commonwealth of Independent States (CIS) and the Eurasian Economic Union (EAEU). We adapt the dossier to the requirements of the target authority and coordinate with distributors and local representatives.
Can our Turkish marketing authorisation dossier be used directly abroad?
Largely yes, but not as it stands. As the Common Technical Document (CTD) structure is based on ICH M4, Modules 2–5 provide a common basis across regions, whereas Module 1 (regional administrative information) differs for each authority and has to be prepared anew. The target country’s pharmacopoeial and specification expectations, stability data suited to its climatic zone, acceptance of the reference product used in the bioequivalence study, and language and labelling rules are also checked. We identify these differences before submission through a gap analysis.
What is eCTD, and where is it used?
eCTD is the electronic format of the CTD dossier, built on an XML backbone. The dossier is submitted in successive submissions called “sequences”, so it is possible to trace which document changed and when throughout the marketing authorisation lifecycle. In the EU, eCTD is mandatory in the centralised, decentralised and mutual recognition procedures and is being made mandatory step by step in national procedures; in Saudi Arabia (SFDA), only eCTD has been accepted since 2015, with an SFDA-specific Module 1; and in Türkiye, marketing authorisation applications are also submitted via e-CTD. Some countries still accept paper CTD, NeeS or PDF-based electronic dossiers. We confirm the target country’s currently accepted format before each submission.
What is ACTD, and how is a CTD dossier converted to ACTD?
The ACTD (ASEAN Common Technical Dossier) is the common dossier format of ASEAN countries and consists of four parts: Part I administrative data and product information, Part II quality, Part III non-clinical and Part IV clinical. In the conversion, the counterpart of CTD Module 1 is prepared anew in Part I for the specific country; Module 3 moves to Part II, Module 4 to Part III and Module 5 to Part IV. The Module 2 summaries, a separate module in the CTD, sit within the relevant parts of the ACTD. The content is reviewed against the ASEAN Common Technical Requirements (ACTR) and ASEAN guidelines; long-term stability data for the hot and humid climatic zone (Zone IVb, 30 °C/75% RH) is one of the most frequent gaps.
How does registration work in the CIS and the Eurasian Economic Union?
The Eurasian Economic Union (Russia, Belarus, Kazakhstan, Kyrgyzstan and Armenia) applies common rules for its single medicines market. Under Decision No. 78 of the Council of the Eurasian Economic Commission, the dossier is prepared in CTD structure with an EAEU-specific Module 1; the application is submitted to a reference state and extended to the other member states through the mutual recognition or decentralised procedure. Modules 1 and 2 and the product information (SmPC, labelling and PIL) are prepared in the local language (mostly Russian), while Modules 4–5 and most of Module 3 may be in English. Authorisation depends on a GMP assessment of all manufacturing sites by the reference state authority, including an on-site inspection against EAEU Good Manufacturing Practice (GMP) rules. The deadline for applying to bring nationally authorised products into line with EAEU rules expired on 31.12.2025. National authorisations of products for which an application was filed by that date may remain valid for a limited period during the harmonisation procedure. CIS countries outside the EAEU, such as Uzbekistan, Azerbaijan and Tajikistan, apply national procedures; dossier format, language requirements and recognition routes vary by country.
What should be considered in MENA and the Gulf?
In the Gulf Cooperation Council countries, the centralised registration procedure (GCC-DR) makes it possible to proceed in several Gulf countries with a single dossier; national applications follow the Module 1 requirements of Saudi Arabia (SFDA) and the other authorities. Most MENA countries require a Certificate of Pharmaceutical Product (CPP) issued in Türkiye, a price certificate in the authority’s template covering origin and reference-country prices, and product information and labelling in Arabic (French in some North African countries); some authorities also require manufacturing site registration, samples for national laboratory testing or an on-site GMP inspection. Stability data meeting Zone IV climatic conditions is also important.
Which dossier format conversions do you carry out?
We convert your existing dossier into the format required by the target authority:
- CTD → ACTD (ASEAN)
- Paper/PDF CTD or NeeS → eCTD (creation of the initial/baseline sequence)
- EU eCTD → Gulf (GCC/SFDA) and other regional eCTDs: new Module 1, re-publishing to the regional specification and technical validation
- CTD/eCTD → EAEU format (EAEU Module 1 and documents in Russian)
- eCTD → NeeS, PDF or paper formats accepted by individual countries
For every conversion, we also report content gaps such as stability, bioequivalence, pharmacopoeia and translation.
How do you start a dossier conversion?
The first step is a gap analysis: your current dossier is compared module by module with the target country’s current guidelines, and data that is missing or must be presented differently is listed. The dossier is then restructured; the CPP, GMP certificate, apostilled or consular-legalised documents and translations are planned; and publishing and technical validation are completed so that the dossier is ready for submission.
How do you manage post-approval changes across several countries?
We assess a change to the core dossier against each country’s variation classification. In the EU, for example, Type IA, Type IB and Type II variations have different timelines and documentation; the EAEU and Gulf authorities have their own classifications. We submit changes as eCTD sequences or in the format the country accepts, and track approval timelines and product information updates country by country.
